Notice: Trading of Rapport Therapeutics halted at 10:24 AM EST due to "LULD pause". Rapport Therapeutics (RAPP) Institutional Ownership $9.07 +1.92 (+26.85%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Rapport Therapeutics (NASDAQ:RAPP)Number ofInstitutional Buyers(last 12 months)38TotalInstitutional Inflows(last 12 months)$168.76MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$2.70M Get RAPP Insider Trade Alerts Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RAPP Institutional Buying and Selling by Quarter Rapport Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Woodline Partners LP181,530$3.22M0.0%-2.7%0.496% 2/17/2025 Deutsche Bank AG2,317$41K0.0%N/A0.006% 2/17/2025 Crestline Management LP27,496$488K0.0%N/A0.075% 2/17/2025 Bank of America Corp DE6,578$117K0.0%-65.6%0.018% 2/17/2025 Acuta Capital Partners LLC16,400$291K0.3%-6.8%0.045% 2/14/2025 Virtus ETF Advisers LLC3,740$66K0.0%N/A0.010% 2/14/2025 T. Rowe Price Investment Management Inc.1,636,931$29.04M0.0%-5.2%4.475% 2/14/2025 Price T Rowe Associates Inc. MD1,143,384$20.29M0.0%+9.2%3.126% 2/14/2025 TRV GP V LLC7,135,233$126.58M43.1%N/A19.506% 2/14/2025 TRV GP VI LLC969,218$17.19M14.7%N/A2.650% Get the Latest News and Ratings for RAPP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025 Barclays PLC18,497$328K0.0%+43.8%0.051% 2/13/2025 Legal & General Group Plc9,523$169K0.0%+947.6%0.026% 2/13/2025 Wells Fargo & Company MN4,824$86K0.0%+38.9%0.013% 2/12/2025 Geode Capital Management LLC210,676$3.74M0.0%+4.4%0.576% 2/12/2025 Alliancebernstein L.P.1,098,415$19.49M0.0%+0.9%3.003% 2/12/2025 Norges Bank48,452$860K0.0%N/A0.132% 2/12/2025 JPMorgan Chase & Co.7,170$127K0.0%+77.8%0.020% 2/11/2025 KLP Kapitalforvaltning AS1,900$34K0.0%N/A0.005% 2/10/2025 Swiss National Bank18,000$319K0.0%N/A0.049% 1/31/2025 New York State Common Retirement Fund3,500$62K0.0%N/A0.010% 1/30/2025 Rhumbline Advisers10,249$182K0.0%-35.3%0.028% 1/24/2025 Jennison Associates LLC62,287$1.11M0.0%N/A0.170% 1/24/2025 China Universal Asset Management Co. Ltd.7,756$138K0.0%N/A0.021% 12/26/2024 JPMorgan Chase & Co.4,033$83K0.0%N/A0.011% 11/19/2024 Barclays PLC12,863$264K0.0%+36.8%0.035% 11/16/2024 Geode Capital Management LLC201,748$4.13M0.0%N/A0.552% 11/15/2024 Barclays PLC12,863$264K0.0%+36.8%0.035% 11/15/2024 State Street Corp58,046$1.19M0.0%N/A0.159% 11/15/2024 Maven Securities LTD29,930$613K0.0%N/A0.082% 11/14/2024 Eventide Asset Management LLC110,401$2.26M0.0%+120.8%0.302% 11/14/2024 Acuta Capital Partners LLC17,600$360K0.3%-12.0%0.048% 11/14/2024 MetLife Investment Management LLC5,710$117K0.0%N/A0.016% 11/13/2024 BNP Paribas Financial Markets1,684$34K0.0%N/A0.005% 11/13/2024 FMR LLC5,486,468$112.36M0.0%+10.1%14.999% 11/13/2024 The Manufacturers Life Insurance Company77,344$1.58M0.0%+2.4%0.211% 11/12/2024 Charles Schwab Investment Management Inc.73,146$1.50M0.0%N/A0.200% 11/7/2024 LMR Partners LLP20,000$410K0.0%-60.0%0.055% 10/23/2024 Values First Advisors Inc.1,507$31K0.0%N/A0.004% 10/3/2024 SG Americas Securities LLC4,934$101K0.0%N/A0.014% 8/27/2024 Logos Global Management LP208,910$4.86M0.4%N/A0.591% 77 Hedge Funds Are Betting On This Off-Radar Mineral (Ad)With surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fact, 77 hedge funds have quietly increased their positions, pouring millions into companies poised to capitalize on this essential commodity. The reason is simple: America currently depends on Canada for 80% of its potash supply.Read my full report now.8/16/2024 Perceptive Advisors LLC748,183$17.40M0.4%N/A2.045% 8/15/2024 The Manufacturers Life Insurance Company75,516$1.76M0.0%N/A0.206% 8/15/2024 Millennium Management LLC116,782$2.72M0.0%N/A0.319% 8/14/2024 Squarepoint Ops LLC16,345$380K0.0%N/A0.045% 8/14/2024 Sandia Investment Management LP5,000$116K0.2%N/A0.014% 8/14/2024 ARCH Venture Management LLC3,728,738$86.73M31.6%N/A10.193% 8/14/2024 Davidson Kempner Capital Management LP10,000$229K0.0%N/A0.027% 8/10/2024 Sofinnova Investments Inc.1,951,562$45.39M2.4%N/A5.516% 8/9/2024 Johnson & Johnson2,498,051$58.11M14.5%N/A7.061% 8/3/2024 TD Asset Management Inc101,522$2.36M0.0%N/A0.287% (Data available from 1/1/2016 forward) RAPP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RAPP shares? During the previous two years, 44 institutional investors and hedge funds held shares of Rapport Therapeutics. The most heavily invested institutionals were TRV GP V LLC ($126.58M), FMR LLC ($112.36M), ARCH Venture Management LLC ($86.73M), Johnson & Johnson ($58.11M), Sofinnova Investments Inc. ($45.39M), T. Rowe Price Investment Management Inc. ($29.04M), and Price T Rowe Associates Inc. MD ($20.29M).Learn more on RAPP's institutional investors. Which institutional investors have been buying Rapport Therapeutics stock? Of the 38 institutional investors that purchased Rapport Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP V LLC ($7.14M), ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), TRV GP VI LLC ($969.22K), Perceptive Advisors LLC ($748.18K), and FMR LLC ($503.12K). How much institutional buying is happening at Rapport Therapeutics? Institutional investors have bought a total of 18,826,653 shares in the last 24 months. This purchase volume represents approximately $168.76M in transactions. Which Rapport Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Rapport Therapeutics stock in the last 24 months: T. Rowe Price Investment Management Inc. ($90.18K), LMR Partners LLP ($30K), Bank of America Corp DE ($12.53K), Rhumbline Advisers ($5.59K), Woodline Partners LP ($5.03K), and Acuta Capital Partners LLC ($3.60K). How much institutional selling is happening at Rapport Therapeutics? Institutional investors have sold a total of 146,936 shares in the last 24 months. This volume of shares sold represents approximately $2.70M in transactions. Related Companies IDYA Institutional Ownership BLTE Institutional Ownership JANX Institutional Ownership GLPG Institutional Ownership TARS Institutional Ownership VERA Institutional Ownership IOVA Institutional Ownership TVTX Institutional Ownership SDGR Institutional Ownership IRON Institutional Ownership This page (NASDAQ:RAPP) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
